Profiling immune cells to understand responses to melanoma treatment
Official title: Phenotypic, Functional, Metabolic and Transcriptomic Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
Run by University Hospital, Grenoble · NCT06154668 · Data updated 2026-11-12
This study is trying to see how a specific cancer treatment affects the immune system in melanoma patients to help find better ways to personalize their care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 707 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Status | Recruiting |
| Started | January 17, 2024 |
| Main results expected | January 2030 |
| Study ends | January 2031 |
| Registry record updated | February 20, 2024 |
| Trial ID | NCT06154668 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histologically confirmed melanoma at any stage (I, II, III, or IV) who can provide informed consent.
✕Probably not a fit
Patients with ocular melanoma or those under legal protection may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate how anti-PD1 immunotherapy affects the immune system in melanoma patients by analyzing the characteristics and responses of circulating immune cells. The focus is on identifying biomarkers that predict patient responses to treatment, which could help tailor therapies to individual needs. By examining the phenotypic, functional, metabolic, and transcriptomic profiles of immune cells, the study seeks to enhance understanding of treatment efficacy and adverse effects. The research will involve both retrospective and prospective components, depending on patient consent.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for melanoma patients undergoing anti-PD1 therapy.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for immunotherapy responses, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with histologically confirmed melanoma (stage I, II, III or IV based on AJCC classification) * Able to sign the informed collection consent for the retrospective part or to express their non-opposition to the research for the prospective part of the study Exclusion Criteria: * Subject under guardianship or subject deprived of freedom * Persons benefiting from special protection (as defined in Articles L1121-5 and L1121-8 of the Public Health Code): minors, pregnant or breastfeeding women, adults protected by law (under guardianship, curatorship or deprived of liberty) and persons hospitalized without their consent (as defined in Articles L3212-1 and L3212-3 of the Public Health Code). * ocular melanoma
Where it's running
-
CHU Grenoble Alpes
Grenoble, France Recruiting
Study contacts
- Principal investigator: Julie Charles, MD, PhD — CHU Grenoble Alpes
- Study coordinator: Julie Charles, MD, PhD
- Email: jcharles@chu-grenoble.fr
- Phone: 476769320
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Melanoma treatment with immunotherapy guided by serial ctDNA testing
This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.
-
Non-invasive skin-tape test to detect melanoma using methylation biomarkers
A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy
This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.
-
Timing of Immunotherapy in Melanoma
This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.